CAD Impact On Clinical Decisions Warrants Guidance Document – Philips Rep
This article was originally published in The Gray Sheet
Executive Summary
The relationship between the performance of computer-aided detection (CAD) technologies and actual clinical outcomes merits clarification from FDA and CMS, according to Philips Nuclear Medicine Chief Medical Officer David Rollo
You may also be interested in...
FFDM Will Ease Access, Enhance Performance Via Telemedicine – CEO Nields
The ability of full-field digital mammography (FFDM) screening devices to download images from regional health facilities to "centers of excellence" will yield a distinct advantage over film mammography, according to Fischer Imaging CEO Morgan Nields
Pitching CT Lung Cancer Screening To Consumers Inadvisable – JAMA Study
Direct-to-consumer marketing of helical computed tomograpy lung cancer screening "is not advisable," according to a decisional and cost effectiveness analysis by Parthiv Mahadevia, MD, Johns Hopkins, et al., published in the Jan. 15 Journal of the American Medical Association
Spiral CT Will Be Compared With Chest X-Ray In NCI Lung Screening Trial
Enrollment in a National Cancer Institute-sponsored lung screening trial comparing spiral CT to chest x-ray will be complete in one to two years, NCI says